Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation

Girish Gilly Munavalli; Siri Knutsen-Larson; Mary P Lupo; Roy G Geronemus

doi:10.1016/j.jdcr.2021.02.018

Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation

JAAD Case Rep. 2021 Apr:10:63-68. doi: 10.1016/j.jdcr.2021.02.018. Epub 2021 Mar 2.

Authors

Girish Gilly Munavalli^{1

2}, Siri Knutsen-Larson³, Mary P Lupo⁴, Roy G Geronemus⁵

Affiliations

¹ Dermatology, Laser and Vein Specialists of the Carolinas, Charlotte, North Carolina.
² Department of Dermatology, the Wake Forest School of Medicine, Winston-Salem, North Carolina.
³ South Dakota Sanford School of Medicine, Vermillion, South Dakota.
⁴ Lupo Center for Aesthetic and General Dermatology, New Orleans, Louisiana.
⁵ Laser and Skin Surgery Center of New York, New York, New York.

No abstract available

Keywords: ACE-I, angiotensin-converting enzyme inhibitor; ACE2, angiotensin-converting enzyme receptor; AngII, angiotensin II; COVID-19; DIR, delayed inflammatory reaction; RAS, renin-angiotensin system; SARS-CoV-2; angiotensin II; angiotensin-converting enzyme inhibitor; delayed inflammatory reaction; delayed inflammatory reaction (DIR); dermal filler; edema; hyaluronic acid; mRNA, messenger RNA.

Publication types

Case Reports